Pharma and biotech stocks
125 companies in this theme
| Company | Price | Change | Market cap | P/E | Dividend |
|---|---|---|---|---|---|
| Eli LillyLLY | $1,415.55 | −1.13% | $1.28T | 46.5 | 0.5% |
| Johnson & JohnsonJNJ | $278.70 | −1.36% | $680.19B | 42.9 | 1.9% |
| AbbVieABBV | $292.82 | −0.59% | $517.59B | 50.4 | 2.4% |
| Roche HoldingROP | CHF 406.20 | −0.76% | CHF 325.56B | 26.7 | 2.4% |
| Merck & Co.MRK | $143.37 | −0.75% | $356.13B | 144.5 | 2.4% |
| NovartisNOVN · SIX | CHF 133.28 | −1.83% | CHF 256.4B | 32.6 | 2.8% |
| AstraZenecaAZN · LSE | 13,802.00 GBp | −1.65% | £217.66B | 26.6 | 1.7% |
| AmgenAMGN | $457.93 | −0.95% | $250.07B | 26.8 | 2.2% |
| Gilead SciencesGILD | $170.26 | +1.60% | $211.18B | — | 1.9% |
| Novo NordiskNOVO.B · Nasdaq Copenhagen | kr 275.50 | −3.42% | kr 1.26T | 11.2 | 4.2% |
| PfizerPFE | $28.47 | −1.35% | $164.5B | 41.2 | 6.0% |
| Vertex PharmaceuticalsVRTX | $534.20 | −0.67% | $135.44B | 34.4 | — |
| Bristol-Myers SquibbBMY | $61.35 | −2.51% | $125.4B | 13.6 | 4.1% |
| SanofiSAN · Euronext Paris | €86.56 | −1.99% | €106.04B | 25.5 | 4.8% |
| GSKGSK · LSE | 1,869.00 GBp | −3.14% | £77.35B | 18.0 | 3.7% |
| Regeneron PharmaceuticalsREGN | $957.76 | +0.56% | $98.52B | 21.1 | 0.4% |
| ModernaMRNA | $206.80 | −3.93% | $87.1B | — | — |
| MerckMRK | €150.75 | +0.70% | €65.09B | 33.9 | 1.5% |
| CSLCSL | $198.54 | −0.51% | $95.48B | — | 2.0% |
| BayerBAYN | €56.14 | −1.51% | €56B | — | 0.2% |
| UCBUCB | €286.80 | −2.81% | €55.69B | 25.7 | 0.5% |
| argenxARGX · NASDAQ | $947.52 | −0.36% | $59.8B | 32.9 | — |
| Galderma GroupGALD | CHF 187.15 | −2.02% | CHF 43.64B | 64.5 | 0.2% |
| Teva Pharmaceutical IndustriesTEVA | $42.62 | +0.12% | $49.67B | 99.0 | — |
| Samsung Biologics207940 | ₩1,381,000.00 | −2.33% | ₩65.83T | 31.2 | — |
| Sun Pharmaceutical IndustriesSUNPHARMA · NSE | ₹1,880.00 | −0.27% | ₹4.48T | 40.9 | 0.9% |
| BeOne MedicinesONC · NASDAQ | $413.26 | +0.48% | $46.98B | 52.7 | — |
| HaleonHLN · LSE | 342.30 GBp | −1.27% | £30.43B | 19.3 | 2.1% |
| Royalty PharmaRPRX | $68.68 | +0.23% | $39.4B | 45.4 | 1.4% |
| BiogenBIIB | $250.79 | −0.34% | $37.07B | 107.2 | — |
| Celltrion068270 | ₩208,500.00 | −2.11% | ₩48.81T | 31.4 | 0.3% |
| ZoetisZTS | $83.48 | −1.08% | $33.92B | 14.1 | 2.5% |
| GenmabGMAB · Nasdaq Copenhagen | kr 3,502.00 | −0.77% | kr 214.45B | 46.2 | — |
| InsmedINSM | $121.86 | −0.83% | $26.96B | — | — |
| Hansoh Pharmaceutical Group3692 | $32.42 | −2.99% | $202.62B | 27.6 | 1.5% |
| United TherapeuticsUTHR | $584.10 | −0.64% | $25.04B | 22.2 | — |
Pharma and biotech at a glance
Pharmaceutical and biotechnology companies research, develop and sell medicines, from large drug makers to smaller biotech firms with a few products in development.
Results depend on clinical trial outcomes, regulatory approvals and patent expiries, when generic competitors arrive. Large groups often pay dividends; young biotech companies rarely do.